In 2019, the United States Food and Drug Administration approved Orphan therapeutic designation to cannabis flavonoid–Caflanone (FBL-03 G). Already, flavonoid studies are expected to begin in the spring to combat pancreatic cancer.
After successful demonstration of its clinical effectiveness in tumor progression in animals suffering from pancreatic cancer, Flavocure, a drug discovery, and development company has received Orphan Drug Status of its leading candidate, cannabis flavonoid Caflanone (FBL-03 G), by the United States Food and Drug Addiction (FDA).
Caflanone is now on schedule for clinical trials to be performed in spring for the prevention of pancreatic cancer. The project has received significant funding from the Pancreatic Cancer Network and Harvard University.
Caflanone and the pancreatic cancer studies that are to come have been addressed by Medical Cannabis Network with the Co-Founder & Executive Vice Chairman, Clark Swanson.
Flavocure’s Caflanone study is progressing at a rapid pace and will reach step 1/2 of clinical trials later this year.
The flavonoids are present in all types of plants, and all cannabis forms include flavonoids, based on the flavonoids they produce. Roughly 6000 flavonoids have now been found in the wild.
Caflanone or FBL-03 G is extracted from the Jamaican Black Swan, an invasive form of cannabis Sativa.
Caflanone has shown successful results in animal models of pancreatic cancer that are difficult to treat in preclinical studies performed at Harvard Medical School.
Cresorol, which is another flavonoid of the same cannabis plant of Black Swan, was initially developed by Flavocure to treat acute myeloid leukemia (AML), also classified as an orphan by the FDA, but it operates on different mechanisms than Caflanone.